Mesenchymal stem cell therapy for cartilage repair - Medipost
Alternative Names: Cartistem; SMUP-IA-01Latest Information Update: 06 Dec 2024
At a glance
- Originator Medipost
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Osteoarthritis
- No development reported Knee injuries